Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "standard"

1714 News Found

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
News | February 10, 2026

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth

Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum


FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
News | February 07, 2026

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy


GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease
News | February 07, 2026

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease

Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype


Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill
News | February 07, 2026

Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill

The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers


Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients
Drug Approval | February 07, 2026

Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors


Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients
Clinical Trials | February 07, 2026

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing


Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
News | February 06, 2026

Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY

On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY


Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
R&D | February 04, 2026

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research

The new service delivers end-to-end support, managing every stage of an epigenomics project


China nod to Darolutamide for metastatic hormone-sensitive prostate cancer
News | February 04, 2026

China nod to Darolutamide for metastatic hormone-sensitive prostate cancer

The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT


Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub
Policy | February 01, 2026

Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub

A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility